North American Educational Forum on Lymphoma, 2010 Announced
The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America! This 2 ½ day program provides people with lymphoma and their loved ones with critical information about making the best decisions on treatment options, patient support issues and the latest in lymphoma research.
Agenda and Speaking Faculty
The Forum's agenda includes general session presentations, panel discussions, disease-specific breakout sessions, patient support topic sessions and a variety of networking opportunities. View Agenda on the Lymphoma Research Foundation's website.
Drs. Crump and Gregory are in the process of assembling more than 35 lymphoma experts and patient support specialists from around the world to present at this year's Forum. View Speaking Faculty on the Lymphoma Research Foundation's website.
Register Now for an early bird discount
http://www.clfoundation.org/sanfrancisco_edforum/index.html
Details:
North American Educational Forum on Lymphoma, 2010
Friday, September 24, 2010 at 8:00am
Hotel Nikko, San Francsico, CA, San Francisco, CA
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
